We herewith attached our reply
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs India Ltd submitted a reply to a BSE and NSE query dated 8 April 2025 regarding a delayed disclosure. The original announcement on 7 April 2025 informed that Mr. Hemang Jagadish Engineer (DIN 02317989), Independent Director, completed his tenure and ceased to be a Director with effect from 31 March 2025. The company explained that under SEBI's Schedule III, disclosures of this nature are required within 7 days, and they had interpreted this as a 7-day window to submit the announcement. They termed the delay as unintentional and assured full compliance with applicable regulations going forward. The Managing Director Mukund Mehta signed the communication.
The stock itself is unlikely to be materially affected as this is a routine regulatory clarification regarding an Independent Director's natural end of tenure, not a sudden resignation. However, the delayed disclosure flag could raise minor corporate governance concerns among vigilant investors tracking compliance quality.